
## Cesar Lopez-Camacho

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1404722/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Development of Viral-Vectored Vaccines and Virus Replicon Particle-Based Neutralisation Assay against Mayaro Virus. International Journal of Molecular Sciences, 2022, 23, 4105.	1.8	3
2	Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses. JCI Insight, 2022, 7, .	2.3	24
3	The antigenic anatomy of SARS-CoV-2 receptor binding domain. Cell, 2021, 184, 2183-2200.e22.	13.5	331
4	Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell, 2021, 184, 2348-2361.e6.	13.5	936
5	Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell, 2021, 184, 2201-2211.e7.	13.5	442
6	Antibody evasion by the P.1 strain of SARS-CoV-2. Cell, 2021, 184, 2939-2954.e9.	13.5	519
7	Platelet activation and aggregation response to dengue virus nonstructural protein 1 and domains. Journal of Thrombosis and Haemostasis, 2021, 19, 2572-2582.	1.9	10
8	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell, 2021, 184, 4220-4236.e13.	13.5	630
9	A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles. Scientific Reports, 2021, 11, 17928.	1.6	7
10	Evaluation of Chimpanzee Adenovirus and MVA Expressing TRAP and CSP from Plasmodium cynomolgi to Prevent Malaria Relapse in Nonhuman Primates. Vaccines, 2020, 8, 363.	2.1	7
11	Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nature Immunology, 2020, 21, 1336-1345.	7.0	1,066
12	Recombinant Plasmodium vivax circumsporozoite surface protein allelic variants: antibody recognition by individuals from three communities in the Brazilian Amazon. Scientific Reports, 2020, 10, 14020.	1.6	8
13	Adenoviral-Vectored Mayaro and Chikungunya Virus Vaccine Candidates Afford Partial Cross-Protection From Lethal Challenge in A129 Mouse Model. Frontiers in Immunology, 2020, 11, 591885.	2.2	19
14	Production and Purification of Zika Virus NS1 Glycoprotein in HEK293 Cells. Methods in Molecular Biology, 2020, 2142, 93-102.	0.4	3
15	Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines. Vaccines, 2020, 8, 307.	2.1	18
16	Drug-cured experimental Trypanosoma cruziÂinfections confer long-lasting and cross-strain protection. PLoS Neglected Tropical Diseases, 2020, 14, e0007717.	1.3	12
17	Antibody testing for COVID-19: A report from theÂNational COVID Scientific Advisory Panel. Wellcome Open Research, 2020, 5, 139.	0.9	179
18	Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. Eurosurveillance, 2020, 25, .	3.9	64

#	Article	IF	CITATIONS
19	Antibody Responses Against Plasmodium vivax TRAP Recombinant and Synthetic Antigens in Naturally Exposed Individuals From the Brazilian Amazon. Frontiers in Immunology, 2019, 10, 2230.	2.2	8
20	Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers. Pathogens, 2019, 8, 216.	1.2	9
21	A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection. Nature Immunology, 2019, 20, 1291-1298.	7.0	60
22	Development of an E2 ELISA Methodology to Assess Chikungunya Seroprevalence in Patients from an Endemic Region of Mexico. Viruses, 2019, 11, 407.	1.5	9
23	Assessment of Immunogenicity and Neutralisation Efficacy of Viral-Vectored Vaccines Against Chikungunya Virus. Viruses, 2019, 11, 322.	1.5	32
24	A Single and Un-Adjuvanted Dose of a Chimpanzee Adenovirus-Vectored Vaccine against Chikungunya Virus Fully Protects Mice from Lethal Disease. Pathogens, 2019, 8, 231.	1.2	21
25	A multi-genotype therapeutic human papillomavirus vaccine elicits potent T cell responses to conserved regions of early proteins. Scientific Reports, 2019, 9, 18713.	1.6	15
26	Optimization of Zika virus envelope protein production for ELISA and correlation of antibody titers with virus neutralization in Mexican patients from an arbovirus endemic region. Virology Journal, 2018, 15, 193.	1.4	11
27	Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. Nature Communications, 2018, 9, 2441.	5.8	69
28	Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine. Vaccine Journal, 2017, 24, .	3.2	20
29	Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models. Scientific Reports, 2017, 7, 46482.	1.6	41
30	Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites: Naturally Acquired Humoral Immune Response and B-Cell Epitope Mapping in Brazilian Amazon Inhabitants. Frontiers in Immunology, 2017, 8, 77.	2.2	26
31	CBFβ and the Leukemogenic Fusion Protein CBFβâ€SMMHC Associate With Mitotic Chromosomes to Epigenetically Regulate Ribosomal Genes. Journal of Cellular Biochemistry, 2014, 115, 2155-2164.	1.2	11
32	Core Binding Factor β (CBFβ) Is Retained in the Midbody During Cytokinesis. Journal of Cellular Physiology, 2014, 229, 1466-1474.	2.0	10
33	Bookmarking Target Genes in Mitosis: A Shared Epigenetic Trait of Phenotypic Transcription Factors and Oncogenes?. Cancer Research, 2014, 74, 420-425.	0.4	33
34	Cytoskeletal protein filamin A is a nucleolar protein that suppresses ribosomal RNA gene transcription. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 1524-1529.	3.3	43
35	The Runx transcriptional co-activator, CBFβ, is essential for invasion of breast cancer cells. Molecular Cancer, 2010, 9, 171.	7.9	56
36	Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood, 2007, 110, 1916-1923.	0.6	190

#	Article	IF	CITATIONS
37	Fatal COVID-19 Outcomes are Associated with an Antibody Response Targeting Epitopes Shared with Endemic Coronaviruses. SSRN Electronic Journal, 0, , .	0.4	3
38	Reduced Neutralization of SARS-CoV-2 B.1.1.7 Variant from Naturally Acquired and Vaccine Induced Antibody Immunity. SSRN Electronic Journal, 0, , .	0.4	2